AI assistant
Phathom Pharmaceuticals, Inc. — Director's Dealing 2025
Dec 3, 2025
32407_dirs_2025-12-02_f2d736e3-d94b-4182-ab84-50ad6d5e956c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Phathom Pharmaceuticals, Inc. (PHAT)
CIK: 0001783183
Period of Report: 2025-11-28
Reporting Person: Basta Steven L (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-11-28 | Common Stock | M | 90000 | — | Acquired | 131625 | Direct |
| 2025-11-28 | Common Stock | F | 48375 | $15.62 | Disposed | 83250 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-11-28 | Performance Shares | $0 | M | 90000 | Disposed | Common Stock (90000) | Direct |
Footnotes
F1: Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.
F2: Each performance stock unit represents a contingent right to receive one share of common stock of the Issuer.
F3: On April 3, 2025, the reporting person was granted 360,000 performance stock units, of which 90,000 vested on September 25, 2025 and an additional 90,000 vested on November 28, 2025, in each case due to the achievement of the applicable stock price hurdle. The remaining performance stock units will vest based on the achievement of stock price hurdles over a period of four years following the grant date, subject to the reporting person's continued service through the date each such stock price hurdle is achieved.